|
|
 |
 |
| |
 Printable version |
Economic assessment of Caelyx
® versus topotecan in advanced ovarian cancer |
Bulletin du Cancer. Volume 90, Number 11, 983-8, Novembre 2003, Dossier thématique
|
 Résumé
Article gratuit
|
Author(s) : Véronique Girre, Éric Pujade‐Lauraine, Isabelle Durand‐Zaleski |
Summary : Ovarian cancer is the most frequent cause of death due to gynecologic malignancy in both the United States and in Europe. A phase III investigation compared second line treatment Caelyx
® with topotecan in patients with advanced epithelial ovarian carcinoma who failed a first‐line platinum‐containing regimen. A total of 474 patients were enrolled. Although no significant advantage of Caelyx
® over topotecan with regards to overall survival and progression was found, there were fewer adverse events in the Caelyx
® arm and Caelyx
® had significantly better quality of life profile. We conducted a cost minimization analysis of both treatment arms. Costs were estimated from the viewpoint of the hospital, over the duration of the study period (12 weeks). The frequency of adverse events was derived from the trial‘s CRF, the treatment patterns of adverse events was estimated for each type of adverse event and each grade for a given type of adverse event. Costs included that of the drug and management of adverse events. Because of uncertainty on actual time spent in French hospitals, administration costs were not valued. Adverse events valued in the analysis were: stomatitis\\pharyngitis, PPE, nausea\\vomiting diarrhea, anemia, thrombocytopenia, neutropenia, sepsis, fever. Drug costs and costs of blood products were valued using the purchase price by the hospital, costs of tests and hospital days were estimated from the hospital‘s accounting system. The drug cost per patient was 8,735 euros for Caelyx
® and 6,196 euros for topotecan, the cost of adverse events were 528 and 3,632 euros for Caelyx
® and topotecan respectively, due to the high rate of adverse events in patient treated with topotecan. The total costs were 9,279 and 9,938 for Caelyx
® and topotecan respectively. Conclusion: the least expensive management for second line advanced ovarian cancer is Caelyx
®. Although the initial cost of the drug is higher, the reduced number of adverse events results in a lower total cost. Because treatment with Caelyx
® is also associated with a better of quality of life, this treatment strategy could be considered dominant. ▴ |
Keywords : Caelyx
®, topotecan, cost |
|
